TherapeuticsMD Announces First Quarter 2016 Financial Results

– NDA filing for TX-004HR planned by end of June 2016 –

– Strong cash position of approximately $182 million to advance
pipeline products –

BOCA RATON, Fla.–(BUSINESS WIRE)–TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative women’s healthcare
company, today announced its first quarter financial results for the
quarter ended March 31, 2016.

First Quarter and Recent Developments

  • Net revenue from the company’s prescription prenatal vitamin business
    increased 10 percent to approximately $4.9 million for the first
    quarter of 2016, compared with approximately $4.5 million for the
    first quarter of 2015.
  • Net loss was approximately $21.0 million for the first quarter of
    2016, compared with approximately $20.9 million for the first quarter
    of 2015.
  • Ended the quarter with approximately $182.1 million in cash and no
  • Presented posters at ENDO 2016 and the International Society for the
    Study of Women’s Sexual Health (ISSWSH) Annual Meeting 2016 detailing
    results of the phase 3 Rejoice Trial for Yuvvexy, the conditionally
    approved trade name for TX-004HR, an applicator-free vaginal estradiol
    softgel drug candidate for the treatment of moderate-to-severe vaginal
    pain during sexual intercourse (dyspareunia), a symptom of vulvar and
    vaginal atrophy (VVA) due to menopause. The findings showed patients
    treated with Yuvvexy achieved a statistically significant improvement
    over placebo across all four co-primary endpoints at all three doses
    evaluated. A New Drug Application filing is planned for Yuvvexy by end
    of June 2016.
  • Exited approximately 1,500 of the 1,750 patients enrolled in the
    Replenish Trial, a phase 3 clinical trial of TX-001HR, a combination
    estradiol and progesterone drug candidate, for the treatment of
    moderate-to-severe vasomotor symptoms due to menopause. Topline
    results are currently anticipated late in the fourth quarter of 2016.
  • Launched VitaTrue™, the first certified vegan and kosher prescription
    prenatal multivitamin, which expands the company’s line of
    prescription prenatal vitamin products and further strengthens its
    women’s health capabilities.
  • Grew the company’s intellectual property portfolio to a current total
    of 134 patent filings, including 72 international filings, with 17
    issued U.S. patents.
  • Strengthened relationships with key medical, pharmacy, patient and
    industry organizations worldwide.

“During the first quarter, we successfully executed on our goals across
the company,” said TherapeuticsMD CEO Robert G. Finizio. “We presented
detailed phase 3 data from the Rejoice Trial at multiple conferences,
and we are preparing to file our NDA for TX-004HR, the first of our two
novel pipeline candidates in development to treat symptoms of menopause.
We also expect topline data late in the fourth quarter of 2016 from our
Replenish Trial for TX-001HR. We remain optimistic about the potential
of our pipeline products and intend to leverage them, along with our
current commercial infrastructure, to establish a leadership position in
women’s health.”

Summary of First Quarter 2016 Financial Results

For the quarter ended March 31, 2016, net revenue from the company’s
prescription prenatal vitamins was approximately $4.9 million compared
with net revenue of approximately $4.5 million for the prior year’s
quarter. Revenue growth during the quarter was primarily driven by an
increase in the number of units sold and an increase in the average
sales price of the company’s prenatal vitamin products, partially offset
by the impact of annual changes in insurance plans.

Cost of goods sold was approximately $1.1 million for the three months
ended March 31, 2016, compared with approximately $1.0 million in the
prior year’s quarter.

Total operating expenses for the first quarter of 2016 included research
and development (R&D) expenses and sales, general and administrative
expenses (SG&A). R&D expenses during the first quarter of 2016 were
approximately $15.1 million compared to approximately $18.2 million
during the prior year’s quarter, reflecting a decline in the company’s
clinical trial costs, partially offset by an increase in scale-up and
manufacturing activities to support commercialization. SG&A expenses for
the first quarter of 2016 were approximately $9.7 million compared with
approximately $6.2 million for the prior year’s quarter, primarily due
to an increase in share-based compensation expense.

Non-operating income was insignificant for the first quarter of both
2016 and 2015 and included primarily interest income for both periods.

Net loss for the first quarter of 2016 was approximately $21.0 million,
or $0.11 per basic and diluted share, compared with approximately $20.9
million, or $0.13 per basic and diluted share, for the first quarter of

At March 31, 2016, cash on hand was approximately $182.1 million,
compared with approximately $64.7 million at December 31, 2015.

Conference Call Today

As previously announced, TherapeuticsMD will host a conference call
today to discuss these financial results and provide a business update.
Details for the call are:


  Tuesday, May 3, 2016


4:30 p.m. EDT

Telephone Access (US):


Telephone Access (International):


Access Code for All Callers:


Additionally, a live webcast can be accessed on the company’s website,,
on the Home Page or under the “Investors & Media” section. A
digital recording of the conference call will be available for replay
beginning two hours after the call’s completion and for at least 30 days
with the dial-in 855-859-2056 or international 404-537-3406 and
Conference ID: 45870409.

About TherapeuticsMD, Inc.

TherapeuticsMD, Inc. is an innovative healthcare company focused on
developing and commercializing products exclusively for women. With its
SYMBODA™ technology, TherapeuticsMD is developing advanced hormone
therapy pharmaceutical products to enable delivery of bio-identical
hormones through a variety of dosage forms and administration routes.
The company’s clinical development pipeline includes two phase 3
products. The company also manufactures and distributes branded and
generic prescription prenatal vitamins as well as over-the-counter
vitamins under the vitaMedMD® and BocaGreenMD®
brands. More information is available at the following websites:,,

This press release by TherapeuticsMD, Inc. may contain
forward-looking statements. Forward-looking statements may include, but
are not limited to, statements relating to TherapeuticsMD’s objectives,
plans and strategies as well as statements, other than historical facts,
that address activities, events or developments that the company
intends, expects, projects, believes or anticipates will or may occur in
the future. These statements are often characterized by terminology such
as “believes,” “hopes,” “may,” “anticipates,” “should,” “intends,”
“plans,” “will,” “expects,” “estimates,” “projects,” “positioned,”
“strategy” and similar expressions and are based on assumptions and
assessments made in light of management’s experience and perception of
historical trends, current conditions, expected future developments and
other factors believed to be appropriate. Forward-looking statements in
this press release are made as of the date of this press release, and
the company undertakes no duty to update or revise any such statements,
whether as a result of new information, future events or otherwise.
Forward-looking statements are not guarantees of future performance and
are subject to risks and uncertainties, many of which are outside of the
company’s control. Important factors that could cause actual results,
developments and business decisions to differ materially from
forward-looking statements are described in the sections titled “Risk
Factors” in the company’s filings with the Securities and Exchange
Commission, including its most recent Annual Report on Form 10-K and
Quarterly Reports on Form 10-Q, as well as reports on Form 8-K, and
include the following: the company’s ability to maintain or increase
sales of its products; the company’s ability to develop and
commercialize its hormone therapy drug candidates and obtain additional
financing necessary therefor; the length, cost and uncertain results of
the company’s clinical trials; the potential of adverse side effects or
other safety risks that could preclude the approval of the company’s
hormone therapy drug candidates; the company’s reliance on third parties
to conduct its clinical trials, research and development and
manufacturing; the availability of reimbursement from government
authorities and health insurance companies for the company’s products;
the impact of product liability lawsuits; the influence of extensive and
costly government regulation; the volatility of the trading price of the
company’s common stock and the concentration of power in its stock
ownership. PDF copies of the company’s historical press releases and
financial tables can be viewed and downloaded at its website:

March 31, 2016 December 31, 2015
Current Assets:
Cash $ 182,097,345 $ 64,706,355
Accounts receivable, net of allowance for doubtful accounts
of $318,061 and $81,910, respectively 5,063,773 3,049,715
Inventory 957,434 690,153
Other current assets   1,718,069     2,233,897  
Total current assets   189,836,621     70,680,120  
Fixed assets, net   264,706     198,592  
Other Assets:
Intangible assets, net 1,694,546 1,615,251
Prepaid expense 1,047,970 1,109,883
Security deposit   125,000     125,000  
Total other assets   2,867,516     2,850,134  
Total assets $ 192,968,843   $ 73,728,846  
Current Liabilities:
Accounts payable $ 3,430,649 $ 3,126,174
Other current liabilities   6,165,764     7,539,526  
Total current liabilities   9,596,413     10,665,700  
Total liabilities   9,596,413     10,665,700  
Commitments and Contingencies
Stockholders’ Equity:
Preferred stock – par value $0.001; 10,000,000 shares authorized;
no shares issued and outstanding
Common stock – par value $0.001; 350,000,000 shares authorized;
196,253,700 and 177,928,041 issued and outstanding, respectively 196,254 177,928
Additional paid-in capital 423,932,401 282,712,078
Accumulated deficit   (240,756,225 )   (219,826,860 )
Total stockholders’ equity   183,372,430     63,063,146  
Total liabilities and stockholders’ equity $ 192,968,843   $ 73,728,846  
Three Months Ended
March 31, 2016 March 31, 2015
Revenues, net $ 4,930,091 $ 4,475,049
Cost of goods sold   1,108,443     1,043,641  
Gross profit   3,821,648     3,431,408  
Operating expenses:
Sales, general, and administrative 9,678,552 6,163,612
Research and development 15,097,017 18,176,835
Depreciation and amortization   19,597     13,572  
Total operating expense   24,795,166     24,354,019  
Operating loss   (20,973,518 )   (20,922,611 )
Other income
Interest income 41,617 18,513
Accreted interest   2,536     9,842  
Total other income   44,153     28,355  
Loss before income taxes (20,929,365 ) (20,894,256 )
Provision for income taxes        
Net loss $ (20,929,365 ) $ (20,894,256 )
Net loss per share, basic and diluted $ (0.11 ) $ (0.13 )
Weighted average number of common
shares outstanding-basic and diluted   194,901,560     163,448,130  
Three Months Ended
March 31, 2016 March 31, 2015
Net loss $ (20,929,365 ) $ (20,894,256 )
Adjustments to reconcile net loss to net cash used in
operating activities:
Depreciation of fixed assets 8,363 6,881
Amortization of intangible assets 11,234 6,691
Provision for doubtful accounts 236,151 13,004
Share-based compensation 4,381,690 840,464
Changes in operating assets and liabilities:
Accounts receivable (2,250,209 ) (502,836 )
Inventory (267,281 ) 222,925
Other current assets 477,312 91,412
Other assets (2,536 ) (9,842 )
Accounts payable 304,475 (91,946 )
Deferred revenue (522,613 )
Other current liabilities (1,373,762 ) 1,038,813
Other long-term liabilities       651,567  
Net cash used in operating activities   (19,403,928 )   (19,149,736 )
Patent costs (90,529 ) (36,853 )
Purchase of fixed assets   (74,478 )    
Net cash used in investing activities   (165,007 )   (36,853 )
Proceeds from sale of common stock, net of costs 134,863,475 59,117,827
Proceeds from exercise of options 786,450 7,208
Proceeds from exercise of warrants   1,310,000     358,400  
Net cash provided by financing activities   136,959,925     59,483,435  
Increase in cash 117,390,990 40,296,846
Cash, beginning of period   64,706,355     51,361,607  
Cash, end of period $ 182,097,345   $ 91,658,453  


TherapeuticsMD, Inc.
Dan Cartwright, 561-961-1900
Financial Officer
Delucia, 561-961-1900
Director of Investor Relations